The current status of aromatase inhibitors in the management of breast cancer

Surgical Clinics of North America

Volumn 83, Issue 4, 2003, Pages 973-994

  Baum, Michael ^a   Buzdar, Aman ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; FOLLITROPIN; FORMESTANE; LETROZOLE; LUTEINIZING HORMONE; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; BREAST CARCINOMA; CANCER RESEARCH; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLLES FRACTURE; DEEP VEIN THROMBOSIS; DISEASE EXACERBATION; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HORMONE INHIBITION; HOT FLUSH; HUMAN; MENOPAUSAL SYNDROME; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; POLYP; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SPINE FRACTURE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VOMITING; WEIGHT GAIN; WRIST FRACTURE;

EID: 0038495565     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(03)00031-8     Document Type: Review

References (57)

1. Peto R, Boreham J, Clark M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years [letter]. Lancet 2000;355:1822.
2. Beatson JT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;ii:104-7, 162-5.
3. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal woman with early breast cancer: first results of the ATAC randomized trial. The ATAC Trialists Group. Lancet 2002;359:2131-9.
4. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancer by adrenalectomy. Cancer Res 1952;12:134-41.
5. Haddow A, Watkinson JM, Patterson E, et al. Influence of synthetic estrogens upon advanced malignant disease. BMJ 1944;2:393-8.
6. Adair FE, Herrman JB. The use of testosterone proprionate in the treatment of advanced carcinoma of the breast. Ann Surg 1946;123:1023-35.
7. Griffiths CT, Hall TC, Saba Z, et al. Preliminary trial of aminogluthimide in breast cancer. Cancer 1973;32:31-7.
8. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7(9):2620-35.
9. Coombes RC, Goss P, Dowsett M, et al. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984;2:1237-9.
10. Buzdar AU, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of an overview analysis of two phase III trials. J Clin Oncol 1996;14(7):2000-11.
11. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83(6):1142-52.
12. Bonneterre J, Buzdar A, Nabholtz JMA, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 2001;92(9):2247-58.
13. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16:453-61.
14. Buzdar A, Douma J, Davidson N, et al. A phase III, multicenter, double-blind, randomized study of letrozole (Femara), an aromatse inhibitor, for advanced breast cancer versus megestrol acetate conducted in the United States, Canada, Denmark, Germany, Italy, Netherlands, and the United Kingdom, J Clin Oncol 2001;19(14):3357-66.
15. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol 1998;9(6):639-45.
16. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000; 18(7):1399-411.
17. Nabholtz JM. Steroidal side effects of exemestane. J Clin Oncol 2001;19(7):2107-8.
18. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women - results of a North American multicenter randomized trial. J Clin Oncol 2000;18(22):3758-67.
19. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women - results of the TARGET (tamoxifen or arimidex randomized group efficacy and tolerability) study. J Clin Oncol 2000;18(22):3748-57.
20. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) versus. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer [abstract 131]. Proc Am Soc Clin Oncol. 2002.
21. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase iii study of the international letrozole breast cancer group. J Clin Oncol 2001a;19(10):2596-606.
22. Mouridsen H, Sun Y, Gershanovich M, et al. Final survival analysis of the double-blind, randomized, multinational phase III trial of letrozole (Femara) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer [abstract]. Breast Cancer Res Treat 2001;69:211 (Abstract 9 and oral presentation at 2001 San Antonio Breast Cancer Meeting).
23. Buzdar AU, Chaudri HA, Trunet PF. Letrozole: which dose to be used? J Clin Oncol 2000;18(8):1802-3.
24. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial [abstract 316]. Proc Am Soc Clin Oncol 2000;19:83a.
25. Hamilton A, Piccart M. The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 1999;10:377-84.
26. Plourde PV, Dyroff M, Dowsett M, et al. Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;53(1-6):175-9.
27. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999;35(2):208-13.
28. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20(3):751-7.
29. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Lancet 10983;I:257-61.
30. Current Trials Working Party of the Cancer Research Campaign in Breast Cancer Trials Group. Preliminary results from the Cancer Research Campaign Trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst 1996;88:1834-9.
31. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
32. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529-42.
33. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
34. Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994b;86: 1534-9.
35. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ 1995; 311:977-80.
36. Love RR, Barden HS, Mazess RB, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Int Med 1994a; 154:2585-8.
37. The American College of Obstetricians and Gynecologists. Tamoxifen and endometrial cancer. Obstet Gynecol 2000;95:1C-3C.
38. Sismondi P, Biglia N, Volpi E, et al. Tamoxifen and endometrial cancer. Ann N Y Acad Sci 1994;734:310-21.
39. Bissett D, Davis JA, George WD. Gynecological monitoring during tamoxifen therapy. Lancet 1994;344:1244.
40. De Muylder X, Neven P, De Somer M, et al. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Obstet 1991;36:127-30.
41. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving long-term tamoxifen. Obstet Gynecol 1993;81:660-4.
42. Neven P, De Muylder X, Van Belle Y, et al. Hysteroscopic follow-up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol 1990;35:235-8.
43. Cutuli B, Petit JC, Fricker JP, et al. Adjuvant tamoxifen in breast cancer treatment in postmenopausal women: occurrence of thromboembolic complications. Oncol Rep 1994; 1:59-63.
44. Jaiyesimi IA, Buzdar A, Decker DA, et al. Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 1995;13:513-29.
45. Meier CR. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 1998;45:608-12.
46. Bergman L, Beelan MLR, Gallee MPW, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7.
47. Lykkesfeldt AE. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncologica 1996;35(Suppl):9-14.
48. Rutqvist LE, Cedermark B, Galas U, et al. Randomized trial of node negative postmenopausal breast cancer. Stockholm Breast Cancer Study Group. Acta Oncol 1992;31(2):265-70.
49. Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Natl Cancer Inst Monogr 1992;11:117-20.
50. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;2:282.
51. Salih AK, Fentiman IS. Breast cancer prevention: present and future. Cancer Treat Rev 2001;27(5):261-73.
52. Cuzick J. Future possibilities in the prevention of breast cancer: breast cancer prevention trials. Breast Cancer Res 2000;2(4):258-63.
53. Duffy SR, Jackson TL. The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) early breast cancer trial in postmenopausal patients: endometrial sub-protocol results. Proceedings of the 2002 meeting of the American Society of Clinical Oncology (ASCO). Available at http://www.asco.org/ac/11003_12-002324-00_29-00A-00_18-002000-00_ 19-00201590.00.asp. Accessed 2003.
54. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol 2001;19:2767.
55. van Poznak C. How are bisphosphonates used today in breast cancer clinical practice? Semin Oncol 2001;28(Suppl 11):69-74.
56. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone-receptor positive breast cancer: status report 2002. J Clin Oncol 2002; 20(15):3317-27.
57. Thürlimann B, Robertson JFR, Bonneterre J, et al. Efficacy of tamoxifen following anastrozole as first-line treatment for advanced breast cancer in postmenopausal patients. Arimidex Study Group. Eur J Cancer 2001;37(Suppl 5):5.